Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 2;14(1):16.
doi: 10.1186/s12987-017-0064-3.

Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease

Affiliations

Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease

Prakash Ambady et al. Fluids Barriers CNS. .

Abstract

Background and purpose: The radiologic features and patterns of primary central nervous system lymphoma (PCNSL) at initial presentation are well described. High response rates can be achieved with first-line high-dose methotrexate (HD-MTX) based regimens, yet many relapse within 2 years of diagnosis. We describe the pattern of relapse and review the potential mechanisms involved in relapse.

Methods: We identified 78 consecutive patients who attained complete radiographic response (CR) during or after first-line treatment for newly diagnosed PCNSL (CD20+, diffuse large B cell type). Patients were treated with HD-MTX based regimen in conjunction with blood-brain barrier disruption (HD-MTX/BBBD); 44 subsequently relapsed. Images and medical records of these 44 consecutive patients were retrospectively reviewed. The anatomical location of enhancing lesions at initial diagnosis and at the time of relapse were identified and compared.

Results: 37/44 patients fulfilled inclusion criteria and had new measureable enhancing lesions at relapse; the pattern and location of relapse of these 37 patients were identified. At relapse, the new enhancement was at a spatially distinct site in 30 of 37 patients. Local relapse was found only in seven patients.

Discussion: Unlike gliomas, the majority of PCNSL had radiographic relapse at spatially distinct anatomical locations within the brain behind a previously intact neurovascular unit (NVU), and in few cases outside, the central nervous system (CNS). This may suggest either (1) reactivation of occult reservoirs behind an intact NVU in the CNS (or ocular) or (2) seeding from bone marrow or other extra CNS sites.

Conclusion: Recognizing patterns of relapse is key for early detection and may provide insight into potential mechanisms of relapse as well as help develop strategies to extend duration of complete response.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Case 1; Axial T1-weighted post contrast imaging at initial presentation (a, b), in complete response (c) after therapy and at relapse (d). At initial presentation, multiple scattered left frontal and callosal lesions are noted (a). Patient achieved complete response after 12 months of HD-MTX treatment (c). 1 year after finishing treatment, relapse was noted in the periventricular white matter of the left lateral ventricle (d)
Fig. 2
Fig. 2
Case 2; Axial T1-weighted post contrast imaging at initial presentation (a, b) and relapse (c, d). Initial presentation shows a localized large enhancing lesion centered in the genus of the corpus callosum (CC) with extension mainly into the right frontal lobe (a, b). After 10 months of HD-MTX treatment there is relapse in the ependymal surface of the left lateral ventricle (d) with complete response in the CC lesion (c)
Fig. 3
Fig. 3
Case 3; Axial T1-weighted post contrast imaging at initial presentation (a, b), after completing therapy with HD-MTX (c) and relapse (d). Initial presentation shows a large enhancing lesion in the left frontal lobe (a) and normal cerebellum (b). Patient was in complete response after completing 1 year of HD-MTX treatment (c) with radiographic relapse in the right cerebellum, 6 years after the initial diagnosis (d)
Fig. 4
Fig. 4
Case 4; Axial T1 WI post contrast imaging at initial presentation (a, b) and relapse (c, d). At initial presentation there is a solitary right cerebellar lesion (a) with normal supra-tentorial compartment (b). After 10 months of high-dose MTX treatment, relapse was noted in the splenium of the CC with extension to the periventricular white matter (d) with no evidence of residual disease in the cerebellum (c)

References

    1. Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Ruda R, Schlegel U, Siegal T, Soussain C, Abacioglu U, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16:e322–e332. doi: 10.1016/S1470-2045(15)00076-5. - DOI - PubMed
    1. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034–5043. doi: 10.1200/JCO.2005.13.524. - DOI - PubMed
    1. Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Roth A, Hertenstein B, von Toll T, Hundsberger T, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036–1047. doi: 10.1016/S1470-2045(10)70229-1. - DOI - PubMed
    1. Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, Korfel A. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006;80:159–165. doi: 10.1007/s11060-006-9165-6. - DOI - PubMed
    1. Herrlinger U, Kuker W, Uhl M, Blaicher HP, Karnath HO, Kanz L, Bamberg M, Weller M. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol. 2005;57:843–847. doi: 10.1002/ana.20495. - DOI - PubMed

MeSH terms

LinkOut - more resources